ArticleMolecular medicine reports2018
MicroRNA‑34a inhibits liver cancer cell growth by reprogramming glucose metabolism.
Article in Molecular medicine reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 48 citations in OpenAlex.
- Understanding the epigenetic regulation of lactylation and aberrant lactate metabolism in cancer: From mechanisms to therapeutic strategies (Review).International journal of oncology · 2026Review
- Let-7a and miR-34a Interplay Potent Suppressive Roles in Hepatocellular Carcinoma via Co-TargetingInternational journal of molecular sciences · 2026Article
- Noncoding RNAs: A Novel Frontier in Liver Cancer Research and Therapy: Implications for Precision Oncology.Sub-cellular biochemistry · 2026Review
- Microbiota-driven epigenetic modifications in gastrointestinal cancer: Implications for pathogenesis and therapeutic strategies.World journal of microbiology & biotechnology · 2025Review
- Pharmaceutical perspectives on oligonucleotide therapeutics and delivery systems.Pharmacological reviews · 2025Review
- Biomarker Panels Associated with Diagnosis and Overall Survival in Hepatocellular Carcinoma Revealed from Protein-Protein and mRNA-miRNA Interaction Networks.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Research progress in the metabolic reprogramming of hepatocellular carcinoma (Review).Molecular medicine reports · 2024Review
- Review
- Metformin inhibits high glucose-induced apoptosis of renal podocyte through regulating miR-34a/SIRT1 axis.Immunity, inflammation and disease · 2024Article
- Review
- The role of noncoding RNAs in metabolic reprogramming of cancer cells.Cellular & molecular biology letters · 2023Review
- Zip Nucleic Acid-Based Genomagnetic Assay for Electrochemical Detection of microRNA-34a.Biosensors · 2023Article
- Concise review: Cancer cell reprogramming and therapeutic implications.Translational oncology · 2022Article
- Genetic Polymorphisms in the 3'-Untranslated Regions ofBiomedicines · 2022Article
- Role of epigallocatechin-3- gallate in the regulation of known and novel microRNAs in breast carcinoma cells.Frontiers in genetics · 2022Article
- Article
- Reference Genes for qPCR-Based miRNA Expression Profiling in 14 Human Tissues.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2022Review
- The comprehensive landscape of miR-34a in cancer research.Cancer metastasis reviews · 2021Review
- Identification of potential key genes and miRNAs involved in Hepatoblastoma pathogenesis and prognosis.Journal of cell communication and signaling · 2021Article
- From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRs) have been proposed as minimally invasive prognostic markers for various types of cancer, including liver cancer, which is one of the most common cancers worldwide. In the present study, the expression of miR‑34a in human liver cancer tissues and cell lines was evaluated and the effects of miR‑34a on cell proliferation, invasion and glycolysis in hepatocellular carcinoma (HCC) cells were determined. The results indicated that miR‑34a was downregulated in human liver cancer tissues. Overexpression of miR‑34a significantly inhibited liver cancer cell proliferation and clone formation. In terms of the underlying mechanism, miR‑34a was indicated to negatively regulate the expression of lactate dehydrogenase A (LDHA), which consequently inhibited LDHA‑dependent glucose uptake in the cancer cells, as well as cell proliferation and invasion. Collectively, these data suggest that miR‑34a functions as a negative regulator of glucose metabolism and may serve as a novel marker for liver cancer prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.